CIBC Asset Management
AXSM icon

CIBC Asset Management’s Axsome Therapeutics AXSM Stock Holding History

CIBC Asset Management’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$287K Hold
1,699
– – ﹤0.01% 1006
2025
Q4 		$310K Buy
+1,699
New +$237K ﹤0.01% 953

Other funds holding AXSM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CIBC Asset Management's AXSM Position: Q1 2026 in Review

CIBC Asset Management held its Axsome Therapeutics (AXSM) position steady in Q1 2026 at 1,699 shares worth $287K. The position accounts for ﹤0.01% of the portfolio, ranked #1006.

CIBC Asset Management first reported a position in AXSM in Q4 2025 and has held it in 2 quarters since. The position peaked at $310K in Q4 2025. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

  • CIBC Asset Management held 1,699 shares of Axsome Therapeutics worth $287K as of Q1 2026.
  • CIBC Asset Management left its Axsome Therapeutics share count unchanged in Q1 2026.
  • Axsome Therapeutics made up ﹤0.01% of CIBC Asset Management's portfolio in Q1 2026, its #1006 holding.
  • CIBC Asset Management first reported a position in Axsome Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • CIBC Asset Management's Axsome Therapeutics position peaked at $310K in Q4 2025.
  • 409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on CIBC Asset Management's 13F filing for Q1 2026, filed 12 May 2026.